Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein

Cancer Research

Volumn 69, Issue 17, 2009, Pages 7079-7087

  Federico, Antonella ^a,c   Pallante, Pierlorenzo ^a,c   Bianco, Mimma ^a   Ferraro, Angelo ^c   Esposito, Francesco ^a   Monti, Maria ^a   Cozzolino, Marianna ^a   Keller, Simona ^a,c   Fedele, Monica ^a   Leone, Vincenza ^a,c   Troncone, Giancarlo ^b,c   Chiariotti, Lorenzo ^a,c   Pucci, Piero ^a   Fusco, Alfredo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 2; POLYCOMB GROUP PROTEIN; PROTEIN CBX7; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METHYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; THYROID CARCINOMA; TUMOR CELL; UPREGULATION;

ACETYLATION; ANIMALS; CADHERINS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; PROTEOMICS; RATS; RATS, INBRED F344; REPRESSOR PROTEINS;

EID: 70149100658     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1542     Document Type: Article

References (46)

1. Gil J, Bernard D, Martinez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004;6:67-72. (Pubitemid 38425732)
2. Bernard D, Martinez-Leal JF, Rizzo S, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005;24:5543-5551 (Pubitemid 43119349)
3. Scott CL, Gil J, Hernando E, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A 2007;104:5389-5394 (Pubitemid 47175690)
4. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007;128:735-745 (Pubitemid 46273581)
5. Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell 2009;136:200-206
6. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin.Mol Cell Biol 2006;26:2560-2569
7. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004;16:239-246
8. Pallante P, Federico A, Berlingieri MT, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 2008;68:6770-6778
9. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumours: a commentary on the second edition. Cancer 1989;63:908-911 (Pubitemid 19063200)
10. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
11. Pallante P, Berlingieri MT, Troncone G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 2005;93:464-471 (Pubitemid 43080022)
12. Fusco A, Berlingieri M, Di Fiore PP, Portella G, Grieco M, Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987;7:3365-3370
13. Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-471 (Pubitemid 43832192)
14. Pierantoni GM, Esposito F, Giraud S, Bienvenut WV, Diaz JJ, Fusco A. Identification of new high mobility group A1 associated proteins. Proteomics 2007;7:3735-3742 (Pubitemid 350022279)
15. Fedele M, Fidanza V, Battista S, et al. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 2006;66:2536-2543
16. Livak KJ, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)). Method Methods 2001;25:402-408
17. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001;15:2069-2082 (Pubitemid 32762051)
18. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489
19. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 2006;13:1554-1563 (Pubitemid 44210358)
20. Ji X, Woodard AS, Rimm DL, Fearon ER. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 1997;8:773-778 (Pubitemid 27287808)
21. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999;51:7274-7279 (Pubitemid 30032106)
22. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-1431 (Pubitemid 35414532)
23. Ehrich M, Nelson M, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005;102:15785-15790 (Pubitemid 41552820)
24. Shevchenko A, Keller P, Scheiffele P, Mann M, Simons K. Identification of components of trans-Golgi network-derived transport vesicles and detergent-insoluble complexes by nanoelectrospray tandem mass spectrometry. Electrophoresis 1997;18:2591-2600 (Pubitemid 28133341)
25. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-5432
26. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982;42:65-82.
27. Rada-Iglesias A, Enroth S, Ameur A, et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 2007;17:708-719 (Pubitemid 46919708)
28. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004;24:306-319 (Pubitemid 38010056)
29. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454
30. Thiery JP, Sleeman J. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142 (Pubitemid 43278296)
31. Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007;73:1297-1307 (Pubitemid 46452588)
32. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202. (Pubitemid 33741894)
33. Bolden JE, Peart M, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784 (Pubitemid 44348499)
34. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
35. Smith CL. A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays 2008;30:15-24.
36. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
37. van Leeuwen F, van Steensel B. Histone modifications: from genome-wide maps to functional insights. Genome Biol 2005;6:113. (Pubitemid 40872770)
38. Li B, Gogol M, Carey M, Lee D, Seidel C, Workman JL. The role of chromatin during transcription. Science 2007;316:1050-1054
39. Koizume S, Tachibana K, Sekiya T, Hirohashi S, Shiraishi M. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res 2002;30:4770-4780 (Pubitemid 35331758)
40. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 2004;48:365-375 (Pubitemid 39360388)
41. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27:7274-7284
42. Hajra KM, Fearon E. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255-268 (Pubitemid 34553304)
43. Huang S, Litt M, Felsenfeld G. Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications. Genes Dev 2005;19:1885-1893 (Pubitemid 41186989)
44. Pal S, Vishwanath S, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004;24:9630-9645 (Pubitemid 39391698)
45. Pal S, Yun R, Datta A, et al. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 2003;23:7475-7487 (Pubitemid 37271449)
46. Kirmizis A, Santos-Rosa H, Penkett CJ, et al. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 2007;449:928-932 (Pubitemid 47598603)